20,375€
1,37%
Echtzeit-Aktienkurs POLYPEPTIDE GROUP SF -,01
Bid:
Ask:
Echtzeit-Chart der POLYPEPTIDE GROUP SF -,01 Aktie
Fundamentaldaten der POLYPEPTIDE GROUP SF -,01 Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2024 [CHF] | 320,83 Mio. | -18,67 Mio. | -18,64 Mio. | -0,57 | - | - | 2,10 |
| 2023 [CHF] | 311,26 Mio. | -56,59 Mio. | -49,98 Mio. | -1,52 | - | - | 2,16 |
| 2022 [CHF] | 282,03 Mio. | 7,60 Mio. | 7,80 Mio. | 0,24 | - | 86,33 | 2,38 |
| 2021 [CHF] | 304,88 Mio. | 64,67 Mio. | 51,07 Mio. | 1,54 | 1,47% | 13,20 | 2,21 |
| 2020 [CHF] | 238,64 Mio. | 40,32 Mio. | 33,53 Mio. | 1,01 | - | 20,09 | 2,82 |
| 2019 [CHF] | 225,36 Mio. | 33,63 Mio. | 28,63 Mio. | 0,87 | - | 23,55 | 2,99 |
| 2018 [CHF] | 207,33 Mio. | 34,01 Mio. | 27,50 Mio. | 0,83 | - | 24,52 | 3,25 |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der POLYPEPTIDE GROUP SF -,01 Aktie
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1996 and is headquartered in Zug, Switzerland.